APNHY - Aspen Pharmacare Holdings Limited

Other OTC - Other OTC Delayed Price. Currency in USD
+0.02 (+0.31%)
At close: 3:14PM EDT
Stock chart is not supported by your current browser
Previous Close6.40
Bid0.00 x 0
Ask0.00 x 0
Day's Range6.42 - 6.67
52 Week Range4.14 - 12.89
Avg. Volume114,948
Market Cap2.936B
Beta (3Y Monthly)1.07
PE Ratio (TTM)6.60
EPS (TTM)0.97
Earnings DateN/A
Forward Dividend & Yield0.21 (3.32%)
Ex-Dividend Date2018-10-04
1y Target EstN/A
Trade prices are not sourced from all markets
  • Aspen's drug to prevent preterm birth approved by FDA

    Aspen's drug to prevent preterm birth approved by FDA

    The U.S. Food and Drug Administration (FDA) has approved Aspen Pharmacare's hydroxyprogesterone caproate (HPC), which is used to prevent preterm birth in pregnant women, the South African drugmaker's CEO said on Thursday. Aspen, which operates in about 56 countries, has said before that it views the United States as presenting targeted growth opportunities for its niche women's health products such as conjugated estrogens, which is used in menopausal hormone therapy. Aspen got the FDA abbreviated new drug application approval in early August for a preservative-free, single-dose vial, Chief Executive Stephen Saad said at the pharmaceutical's annual result presentation.

  • Should Value Investors Buy ASPEN PHARMACR (APNHY) Stock?

    Should Value Investors Buy ASPEN PHARMACR (APNHY) Stock?

    Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

  • GuruFocus.com

    GuruFocus Value Idea Contest: May Update

    We already have one winner! But you can still enter

  • Reuters

    South Africa's Aspen sells Australian prescription portfolio to Mylan

    Aspen Pharmacare said on Monday that Mylan NV had exercised an option to buy the South African drugmaker's portfolio of prescription and over-the-counter products in Australia for 188 million Australian dollars ($130 million). In December, Aspen said its wholly owned subsidiary incorporated in Mauritius, Aspen Global Incorporated, and its Australian subsidiaries had entered into a distribution arrangement with Alphapharm, a subsidiary of Mylan in respect of the portfolio commercialized in Australia and New Zealand. "The divestment is in line with the group's ongoing portfolio management approach and its stated intention to not only acquire value enhancing products, but to also divest of non-core assets, thereby ensuring enhanced operational focus," Aspen said in a statement.